Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT05911711 Recruiting - Sepsis Clinical Trials

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

Start date: July 7, 2023
Phase:
Study type: Observational [Patient Registry]

Sepsis, a severe response to bacterial infection, lacks understanding of immunometabolic features that can identify high-risk patients. This study aimed to discover immune, biological, and metabolic biomarkers in sepsis patients with poor prognosis and understand the underlying mechanisms of host immune responses.

NCT ID: NCT05911451 Recruiting - Clinical trials for Arteriovenous Fistula

Optimizing Access Surgery In Senior Hemodialysis Patients

OASIS
Start date: December 1, 2019
Phase: N/A
Study type: Interventional

The number of elderly hemodialysis patients is growing. Vascular access complications are a major determinant of the quality of life and health care costs for these vulnerable patients. The three different types of vascular access, i.e. autologous arteriovenous fistulas, arteriovenous grafts, and central venous catheters, have never been compared in randomized controlled trials. This project will deliver the much-needed evidence to determine the optimal strategy for vascular access creation in elderly hemodialysis patients in order to deliver better health care at lower costs.

NCT ID: NCT05909683 Recruiting - Sepsis Clinical Trials

Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

MODIFY
Start date: September 14, 2023
Phase: Phase 3
Study type: Interventional

MODIFY is a randomized, open-labeled, and prospective study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to change the traditional approach for the management of severe infections by integrating the results of BCID2, Reveal Rapid AST, and PCT, to improve patients' outcomes. Early and precise identification of the underlying causative pathogen along with the fast acquisition of the antimicrobial sensitivity results may positively impact the uncontrolled antimicrobial prescription.

NCT ID: NCT05909384 Completed - Sepsis Clinical Trials

Management of Sepsis in Resource Limited Settings Using a Delphi Method.

Start date: May 16, 2023
Phase:
Study type: Observational

Rapid evolution of sepsis syndromes means that timely diagnosis and treatment are critical in improving outcomes but this may be difficult to achieve in many low- and middle- income countries (LMICs) and there is a lack of high quality clinical evidence to guide diagnosis and management in LMIC settings. The wide variability in health systems in LMICs means that additional areas of guidance may be required where staff or facilities are lacking. In the absence of clinical data, to address some of these issues, the investigators aim to use Delphi methodology to obtain experts consensus statements on some specific aspects of sepsis management in LMICs.

NCT ID: NCT05908162 Recruiting - Sepsis Clinical Trials

Algorithm for Predicting the Unfavorable Course of Sepsis in Children

Start date: July 1, 2021
Phase:
Study type: Observational

A comprehensive strategy will be used to investigate the relationship and correlation between 4 diagnostically significant markers relevant for early diagnosis and prediction of complications and death in the development of sepsis in children (C-reactive protein, procalcitonin, presepsin and lipopolysaccharide binding protein). For the first time, an attempt will be made to assess the genetic characteristics of the patient's from the point of view of predisposition to the unfavorable development of the sepsis based on the study of polymorphism of a number of genes of the immune system (tumor necrosis factor beta; interleukin 6, 8, 10; lymphotoxin alpha, etc.). Based on the study results, an algorithm to predict the unfavorable course of sepsis in children will be developed using a comprehensive assessment of biochemical and molecular genetic markers.

NCT ID: NCT05900284 Enrolling by invitation - Sepsis Clinical Trials

Safety and Feasibility of Metformin for Sepsis Induced AKI

Start date: November 8, 2023
Phase: Phase 2
Study type: Interventional

Acute kidney injury (AKI) is an independent risk factor for death that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit. Sepsis is the most frequent cause of AKI, affecting 48 million people worldwide every year, and accounting for approximately 11 million of annual global deaths. Despite these figures, there are no known therapies to prevent or reverse septic AKI; hence this study aims to establish the safety and feasibility of the implementation of metformin in the treatment of AKI in patients with sepsis. This study is the first critical step to inform the design of a future, full-scale efficacy randomized clinical trial.

NCT ID: NCT05897151 Recruiting - Sepsis Clinical Trials

Continuous Spinal Anesthesia Versus General Anesthesia in Sepsis

Start date: June 10, 2023
Phase: Phase 4
Study type: Interventional

The anesthetic efficacy and safety of continuous spinal anesthesia and comparing it with general anesthesia technique in sepsis diagnosed patient.

NCT ID: NCT05896462 Completed - Antisepsis Clinical Trials

Effect of Skin Antisepsis After Skin Closure on Wound Infection After Abdominal Surgery for Sepsis: a Preliminary Report

Start date: August 19, 2019
Phase: N/A
Study type: Interventional

The benefits of pre-incision skin antisepsis is well established. However, the role of skin antisepsis after skin closure in abdominal surgery for sepsis is not well reported. This study examined whether the use of skin antisepsis after closing the skin during a surgery for an infection within the abdomen would have an effect on wound infection in the post-operative period. The patients - aged 18 years and above - were categorised into two groups: the first had antisepsis with povidone iodine-soaked gauze while the second group of patients had their wound only dressed with a dry sterile gauze. Both groups were then compared for the occurrence of surgical site infection and other post-operative outcomes. The null hypothesis was that intra-operative skin antisepsis after skin closure following abdominal surgeries would have no effect on the incidence of post-operative Surgical Site Infection while the alternative hypothesis was that intra-operative skin antisepsis after skin closure following abdominal surgeries would have an effect on the incidence of post-operative Surgical Site Infection.

NCT ID: NCT05895240 Recruiting - Septic Shock Clinical Trials

Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality

MUNI-SEP
Start date: May 1, 2023
Phase: Phase 4
Study type: Interventional

The study will enhance the theory in the frame of reference on the efficacy of Ulinastatin while managing sepsis and subsequent morbidity and mortality. Moreover, the present study will explore Ulinastatin's prophylactic role in progression of multiple organ dysfunctions. Furthermore, the study will have the clinical implications in predicting the ICU admitted patient's stay and related cost in the context of new drug. Current researches will explore the new dimensions in Pakistan's healthcare facilities, paving the way of future academics to analyze it in order to enhance healthcare outcomes.

NCT ID: NCT05893420 Recruiting - COVID-19 Clinical Trials

A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical teams are then directed toward standardized guidance to determine next steps in care for elevated-risk patients. The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.